Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 329-334

  De Groot Besseling, Renate R J ^a   Ruers, Theo J M ^a   Van Kraats, Annemieke A ^a   Poelen, Geert J M ^b   Ruiter, Dirk J ^a   De Waal, Robert M W ^a   Westphal, Johan R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Angiogenesis; Angiostatin; Captopril; TPA

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; CAPTOPRIL; DRINKING WATER; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CIRCULATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; HUMANS; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATORS; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 4544314006     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20400     Document Type: Article

References (43)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
4. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996;32A:2534-9.
5. Westphal JR, Ruiter DJ, de Waal RM. Anti-angiogenic treatment of human cancer: pitfalls and promises. Int J Cancer 2000;86:870-3.
6. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
7. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
8. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998;95:6367-72.
9. Holmgren L, O'Reilly M, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
10. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
11. te-Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel-Rinkes IH. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002;89:1302-9.
12. Galaup A, Opolon P, Bouquet C, Li H, Opolon D, Bissery MC, Tursz T, Perricaudet M, Griscelli F. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 2003;7:731-40.
13. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR. Potentiation of the anti-tumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
14. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-91.
15. Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997;57:1329-34.
16. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997;94:10868-72.
17. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 161:6845-52.
18. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5.
19. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-10.
20. Kerkela E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kahari VM, Saarialho-Kere U. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 2002;198:258-69.
21. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
22. Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 2003;63:4275-80.
23. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000;19:97-107.
24. van Muijen GN, Cornelissen LM, Jansen CF, Figdor CG. Johnson JP, Brocker EB, Ruiter DJ. Antigen expression of metastasizing and nonmetastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 1991;9:259-72.
25. Westphal JR, van't Hullenaar RG, Geurts-Moespot A, Sweep FCJG, Verheijen JH, Bussemakers MMG, Askaa J, Clemmensen I, Eggermont AM, Ruiter DJ, de Waal RM. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 2000;86:760-7.
26. Joe YA, Hong YK, Chung DS, Yang YJ, Kang JK, Lee YS, Chang SI, You WK, Lee H, Chung SI. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 1999;82:694-9.
27. MacDonald NJ, Murad AC, Fogler WE, Lu Y, Sim BK. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 1999;264:469-77.
28. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999;96:5728-33.
29. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, Deford ME, Castellino FJ, Kramer RA, Trail PA. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 1998;247:414-9.
30. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997;272:22924-8.
31. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
32. Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anti Canc Agents 2002;2:667-81.
33. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003;95:388-99.
34. Soff GA, Rossbach HC, Hoppin EC, Cundiff D, Schultz R, Kunz P. Therapeutic application of an angiostatic cocktail for patients with refractory cancer. Proc Am Assoc Cancer Res 2000;41:308.
35. Vogt B, Frey FJ. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997;349:1148.
36. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
37. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-9.
38. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999;81:761-6.
39. de Vries TJ, van Muijen GN, Ruiter DJ. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 1996;6:79-88.
40. Nagase H. Activation mechanisms of matrix metalloproteinases, Biol Chem 1997;378:151-60.
41. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997;16:2319-32.
42. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003;3:589-601.
43. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33.